Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
₹10 Cr
Revenue (TTM)
₹9 Cr
Net Profit (TTM)
₹-76 Cr
ROE
0 %
ROCE
0 %
P/E Ratio
--
P/B Ratio
-0
Industry P/E
26.59
EV/EBITDA
-43.2
Div. Yield
0 %
Debt to Equity
-0.1
Book Value
₹--
EPS
₹-47.3
Face value
10
Shares outstanding
29,816,300
CFO
₹867.64 Cr
EBITDA
₹-165.15 Cr
Net Profit
₹-1,003.91 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Parenteral Drugs
| -28.4 | -4.9 | -7.9 | -- | -- | -21.9 | -24.9 |
|
BSE Healthcare*
| -4.7 | -5.8 | -5.4 | 1.3 | 23.7 | 14.0 | 10.6 |
|
Company
|
2022
|
2019
|
2018
|
2017
|
2016
|
|---|---|---|---|---|---|
|
Parenteral Drugs
| 6.6 | -58.0 | -65.1 | 15.1 | -60.7 |
|
BSE Small Cap
| -1.8 | -6.8 | -23.4 | 59.6 | 1.8 |
|
BSE Healthcare
| -12.1 | -3.5 | -5.9 | 0.5 | -12.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Pledging Gamble Sours for these Companies
2 min read•By Vikas Vardhan
Parenteral Drugs (India) Limited operates as a healthcare company in India. The company manufactures pharmaceutical products, including intravenous infusion, inhalation, veterinary infusion, etc. It also offers IV fluids, such as carbohydrates and... electrolytes, diuretics, dialysis and irrigation solutions, anti-infective and anti-fungal products, and others; and oncology and anaesthesia products. The company also exports its products to Iraq, Yemen, Mozambique, Ghana, Kenya, Kyrgyzstan, Uzbekistan, Sudan, Vietnam, Cambodia, Liberia, Sri Lanka, Nepal, Myanmar, and Cameroon. The company was incorporated in 1983 and is based in Indore, India. Read more
Incorporated
1983
Chairman
Manohar Lal Gupta
Managing Director
Vinod Kumar Gupta
Headquarters
Mumbai, Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
The share price of Parenteral Drugs (India) Ltd is ₹2.90 (NSE) and ₹3.39 (BSE) as of 21-Aug-2023 IST. Parenteral Drugs (India) Ltd has given a return of --% in the last 1 years.
Since, TTM earnings of Parenteral Drugs (India) Ltd is negative, P/E ratio is not available.
The P/B ratio of Parenteral Drugs (India) Ltd is -0.01 times as on 21-Aug-2023, a 100 discount to its peers’ median range of 4.49 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
0.00
|
-0.01
|
|
2020
|
0.00
|
-0.01
|
|
2019
|
0.00
|
-0.05
|
|
2018
|
0.00
|
-0.12
|
|
2017
|
0.00
|
-0.29
|
The 52-week high and low of Parenteral Drugs (India) Ltd are Rs -- and Rs -- as of 03-Apr-2026.
Parenteral Drugs (India) Ltd has a market capitalisation of ₹ 10 Cr as on 21-Aug-2023. As per SEBI classification, it is a Small Cap company.
Before investing in Parenteral Drugs (India) Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
₹0.05
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.